Univariate analysis | Multivariate analysis | |||||
Model 1 | Model 2 | |||||
Variable | Hazard ratio | P | Hazard ratio | P | Hazard ratio | P |
Age at diagnosis (y) | 1.008 (0.96–1.05) | 0.742 | ||||
18F-FDG SUV (≥8.28) | 1.913 (0.62–5.89) | 0.258 | ||||
18F-FES SUV (<2.63) | 13.459 (3.73–48.61) | <0.001* | 10.727 (1.16–99.35) | 0.037* | ||
18F-FDG/FES SUV ratio (≥2.72) | 7.553 (2.04–27.98) | 0.002* | 2.215 (0.39–12.53) | 0.368 | ||
FIGO stage (stage III–IV) | 12.374 (4.05–37.78) | <0.001* | 8.838 (1.09–71.84) | 0.042* | 3.588 (0.50–25.77) | 0.204 |
Histopathologic type (G3 and other) | 6.104 (2.04–18.28) | 0.001* | 0.433 (0.05–3.49) | 0.432 | 1.615 (0.38–6.91) | 0.518 |
Myometrial invasion (≥1/2) | 3.641 (1.26–10.53) | 0.017* | 3.331 (0.50–22.33) | 0.215 | 1.279 (0.26–6.22) | 0.760 |
LVSI (present) | 7.797 (2.16–28.11) | 0.002* | 0.972 (0.13–7.02) | 0.977 | 1.655 (0.24–11.24) | 0.606 |
Tumor size (≥2 cm) | 4.393 (0.98–19.77) | 0.054 | ||||
Lymph node metastasis (present) | 12.502 (4.12–37.99) | <0.001* | 0.443 (0.05–3.76) | 0.456 | 1.270 (0.20–8.30) | 0.803 |
↵* P < 0.05.
Data in parentheses are 95% CIs.